


Sultiame

Cat. No.:	HY-108316		
CAS No.:	61-56-3		
Molecular Formula:	C ₁₀ H ₁₄ N ₂ O ₄ S ₂		
Molecular Weight:	290.36		
Target:	Carbonic Anhydrase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (172.20 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.4440 mL	17.2200 mL	34.4400 mL	
		5 mM	0.6888 mL	3.4440 mL	6.8880 mL	
10 mM		0.3444 mL	1.7220 mL	3.4440 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (4.31 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.25 mg/mL (4.31 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.25 mg/mL (4.31 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	Sultiame is a carbonic anhydrase inhibitor, widely used as an antiepileptic agent.
In Vitro	<p>Sultiame (Sulthiame) is a sulphonamide, and it may exerts antiepileptic activity by producing a modest intracellular acidosis in central neurons via acting as a carbonic anhydrase inhibitor, thereby reducing the frequency of action potentials and epileptiform bursts^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

[1]. Milburn-McNulty P, et al. Sulthiame add-on therapy for epilepsy. Cochrane Database Syst Rev. 2015 Oct 28;(10):CD009472.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA